Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study

Abstract Background Pulmonary exacerbations (PEx) are a major driver of morbidity and mortality in cystic fibrosis and reducing their frequency by extending the time between them is an important therapeutic goal. Although treatment decisions for exacerbations are often made based on dynamic changes...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Julia C. Espel, Hannah L. Palac, Joanne F. Cullina, Alexandria P. Clarke, Susanna A. McColley, Michelle H. Prickett, Manu Jain
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2017-11-01
Cyfres:BMC Pulmonary Medicine
Pynciau:
Antibiotics
Bronchiectasis
Cystic fibrosis
Exacerbation
Outcomes Pseudomonas aeruginosa
Mynediad Ar-lein:http://link.springer.com/article/10.1186/s12890-017-0503-6
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg